What type of study is this?

This is a Quantitative Study study (also classified as: Experimental Study).

September 18, 2025Open Access

Chemical modulation of the unfolded protein response reveals an antiviral role for the PERK pathway in human coronavirus 229E infection

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals thapsigargin-induced activation of the UPR and its effect on HCoV-229E, highlighting elements of the PERK pathway.

Activation of the PERK pathway inhibits HCoV-229E infection, showcasing its antiviral potential.
Thapsigargin treatment in A549 cells effectively suppresses viral replication by reducing double-stranded RNA accumulation.
IRE1 and ATF6 pathways were found not to affect the antiviral effect of thapsigargin against HCoV-229E.
PERK pathway activation also demonstrates substantial inhibition of SARS-CoV-2 replication, suggesting broader antiviral efficacy.

Pellizzari-Delano et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark